MHC-independent tumor antigens for cancer immunotherapy

Cancer is still the main cause of death despite
the development of many treatment
strategies, including extensive radiation and
chemotherapy. Clinical and research results
from animal test have shown that, besides
viruses, bacteria and parasites, the T-cell
system can also recognize malignant abnormal
cells and is able to destroy those.
Especially CD8+ T-cells (cytotoxic T lymphocytes,
CTLs) can cause responses of
tumor repulsion by the recognition of antigens
that are presented on the cell surface
by Major Histocompatibility Complex Class I
molecules (MHC, in humans HLA Class I).
This invention offers the application of HLAindependent
recognition of tumorassociated
antigens for diagnosis, therapy
and prevention of melanoma and other tumor
types. Two antigens are presented that
can be recognized by CTLs independently
of HLA and whose application in cancer
immune therapy will unlock new therapy
alternatives.
[Reference HMZ077]

Further information: PDF

IMG Innovations-Management GmbH
Phone: +49 (0)631/31668-50

Contact
Dr. Klaus Kobek

As Germany's association of technology- and patenttransfer agencies TechnologieAllianz e.V. is offering businesses access to the entire range of innovative research results of almost all German universities and numerous non-university research institutions. More than 2000 technology offers of 14 branches are beeing made accessable to businesses in order to assure your advance on the market. At www.technologieallianz.de a free, fast and non-bureaucratic access to all further offers of the German research landscape is offered to our members aiming to sucessfully transfer technologies.